 |
|
|
| |
C-EDGE CO-STAR: Efficacy of Elbasvir/Grazoprevir Fixed-Dose
Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs
on Opioid Agonist Therapy
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Dore GJ1; Altice F2; Litwin AH3; Dalgard O4; Gane E5; Shibolet O6; Luetkemeyer A7; Nahass R8; Peng CY9; Conway B10; Grebely J1; Howe A11; Nguyen B-Y11; Wahl J11; Barr E11; Robertson M11; Platt HL11
1The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; 2Yale University School of Medicine, New Haven, CT, USA; 3Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA; 4Institute of Clinical Medicine, Oslo, Norway; 5Auckland Clinical Studies, Auckland, New Zealand; 6Tel-Aviv Medical
Center, Tel Aviv, Israel; 7University of California, San Francisco, San Francisco, CA, USA; 8ID Care, Hillsborough, NJ, USA; 9China Medical University Hospital, Taichung, Taiwan; 10Vancouver Infectious Diseases Centre, Vancouver, BC, Canada; 11Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
